• Shashank Gupta, Sandeep Tyagi, and William R Bishai.
• Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.
• Antimicrob. Agents Chemother. 2015 Jan 1;59(1):673-6.

AbstractBedaquiline is a newly approved drug for the treatment of multidrug-resistant tuberculosis, but there are concerns about its safety in humans. We found that the coadministration of verapamil with subinhibitory doses of bedaquiline gave the same bactericidal effect in mice as did the full human bioequivalent bedaquiline dosing. Adding verapamil to bedaquiline monotherapy also protected against the development of resistant mutants in vivo. The adjunctive use of verapamil may permit use of lower doses of bedaquiline to be used and thereby reduce its dose-related toxicities in tuberculosis patients.Copyright © 2015, American Society for Microbiology. All Rights Reserved.

33 keywords...

hide…